Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125


Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.

Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM.

Cancer. 2010 Mar 1;116(5):1234-42. doi: 10.1002/cncr.24816.


Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.


Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.

Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S, Arpino G.

Breast Cancer Res Treat. 2012 Dec;136(3):795-804. doi: 10.1007/s10549-012-2315-y.


Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.

Zhang M, Zhang X, Zhao S, Wang Y, Di W, Zhao G, Yang M, Zhang Q.

Target Oncol. 2014 Dec;9(4):349-57.


Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.

Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y.


Primary breast cancer phenotypes associated with propensity for central nervous system metastases.

Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R.

Cancer. 2006 Aug 15;107(4):696-704.


Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.

Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU.

Breast Cancer Res. 2012 Oct 1;14(5):R129. doi: 10.1186/bcr3324.


Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.

Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, Lyerly HK.

Breast Cancer Res. 2012 Apr 17;14(2):R62.


Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.

Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K.

J Clin Oncol. 2008 Dec 10;26(35):5697-704. doi: 10.1200/JCO.2007.15.8659.


The influence of young age on outcome in early stage breast cancer.

Fowble BL, Schultz DJ, Overmoyer B, Solin LJ, Fox K, Jardines L, Orel S, Glick JH.

Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33.


Age related influence of triple receptor status on metastatic breast cancer post relapse survival.

Todorovic-Rakovic N, Neskovic-Konstantinovic Z.

J BUON. 2013 Oct-Dec;18(4):851-8.


Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.

Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT.

Cancer. 2007 Feb 15;109(4):658-67. Erratum in: Cancer. 2009 May 1;115(9):2024. Reseetkova, Erika [corrected to Resetkova, Erika].


Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.

Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nolè F, Goldhirsch A.

J Clin Oncol. 2009 Dec 1;27(34):5693-9. doi: 10.1200/JCO.2009.22.0962.


Is Ki-67 expression prognostic for local relapse in early-stage breast cancer patients treated with breast conservation therapy (BCT)?

Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, Schiff D, Moran MS.

Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):344-8. doi: 10.1016/j.ijrobp.2013.05.052.


Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.

Brower ST, Ahmed S, Tartter PI, Bleiweiss I, Amberson JB.

Ann Surg Oncol. 1995 Sep;2(5):440-4.


The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.

Chae YK, Gagliato Dde M, Pai SG, Carneiro B, Mohindra N, Giles FJ, Ramakrishnan-Geethakumari P, Sohn J, Liu S, Chen H, Ueno N, Hortobagyi G, Gonzalez-Angulo AM.

PLoS One. 2016 Apr 7;11(4):e0152585. doi: 10.1371/journal.pone.0152585.


Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.

Elledge RM, Clark GM, Chamness GC, Osborne CK.

J Natl Cancer Inst. 1994 May 4;86(9):705-12.


Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.

Kurebayashi J, Kanomata N, Shimo T, Yamashita T, Aogi K, Nishimura R, Shimizu C, Tsuda H, Moriya T, Sonoo H.

Breast Cancer. 2014 Mar;21(2):214-22. doi: 10.1007/s12282-012-0380-z.


Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer.

Rugo HS, Brufsky AM, Ulcickas Yood M, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA.

Breast Cancer Res Treat. 2013 Oct;141(3):461-70. doi: 10.1007/s10549-013-2697-5.

Items per page

Supplemental Content

Support Center